{"id":36338,"date":"2026-10-26T17:15:00","date_gmt":"2026-10-26T11:45:00","guid":{"rendered":"https:\/\/www.delveinsight.com\/blog\/?p=36338"},"modified":"2026-10-26T13:15:42","modified_gmt":"2026-10-26T07:45:42","slug":"expansion-of-glp-1-drugs","status":"publish","type":"post","link":"https:\/\/www.delveinsight.com\/blog\/expansion-of-glp-1-drugs","title":{"rendered":"GLP-1 Drugs Are Moving Beyond Weight Loss\u2014But How Big Can the Opportunity Become?"},"content":{"rendered":"<div id=\"ez-toc-container\" class=\"ez-toc-v2_0_85 counter-hierarchy ez-toc-counter ez-toc-white ez-toc-container-direction\">\n<p class=\"ez-toc-title\" style=\"cursor:inherit\">Table of Contents<\/p>\n<label for=\"ez-toc-cssicon-toggle-item-6adf472d46e9a\" class=\"ez-toc-cssicon-toggle-label\"><span class=\"\"><span class=\"eztoc-hide\" style=\"display:none;\">Toggle<\/span><span class=\"ez-toc-icon-toggle-span\"><svg style=\"fill: #999;color:#999\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" class=\"list-377408\" width=\"20px\" height=\"20px\" viewBox=\"0 0 24 24\" fill=\"none\"><path d=\"M6 6H4v2h2V6zm14 0H8v2h12V6zM4 11h2v2H4v-2zm16 0H8v2h12v-2zM4 16h2v2H4v-2zm16 0H8v2h12v-2z\" fill=\"currentColor\"><\/path><\/svg><svg style=\"fill: #999;color:#999\" class=\"arrow-unsorted-368013\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"10px\" height=\"10px\" viewBox=\"0 0 24 24\" version=\"1.2\" baseProfile=\"tiny\"><path d=\"M18.2 9.3l-6.2-6.3-6.2 6.3c-.2.2-.3.4-.3.7s.1.5.3.7c.2.2.4.3.7.3h11c.3 0 .5-.1.7-.3.2-.2.3-.5.3-.7s-.1-.5-.3-.7zM5.8 14.7l6.2 6.3 6.2-6.3c.2-.2.3-.5.3-.7s-.1-.5-.3-.7c-.2-.2-.4-.3-.7-.3h-11c-.3 0-.5.1-.7.3-.2.2-.3.5-.3.7s.1.5.3.7z\"\/><\/svg><\/span><\/span><\/label><input type=\"checkbox\"  id=\"ez-toc-cssicon-toggle-item-6adf472d46e9a\"  aria-label=\"Toggle\" \/><nav><ul class='ez-toc-list ez-toc-list-level-1 ' ><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-1\" href=\"https:\/\/www.delveinsight.com\/blog\/expansion-of-glp-1-drugs\/#From_Glycemic_Control_to_Global_Phenomenon_A_Quick_Recap\" >From Glycemic Control to Global Phenomenon: A Quick Recap<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-2\" href=\"https:\/\/www.delveinsight.com\/blog\/expansion-of-glp-1-drugs\/#Expanding_Beyond_Weight_Loss_The_Growing_Therapeutic_Potential_of_GLP-1s\" >Expanding Beyond Weight Loss: The Growing Therapeutic Potential of GLP-1s<\/a><ul class='ez-toc-list-level-3' ><li class='ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-3\" href=\"https:\/\/www.delveinsight.com\/blog\/expansion-of-glp-1-drugs\/#Cardiovascular_Disease_The_Indication_That_Changed_the_Payer_Conversation\" >Cardiovascular Disease: The Indication That Changed the Payer Conversation<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-4\" href=\"https:\/\/www.delveinsight.com\/blog\/expansion-of-glp-1-drugs\/#MASH_and_the_Liver_Reversing_Damage_Not_Just_Managing_Risk\" >MASH and the Liver: Reversing Damage, Not Just Managing Risk<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-5\" href=\"https:\/\/www.delveinsight.com\/blog\/expansion-of-glp-1-drugs\/#Chronic_Kidney_Disease_Renal_Protection_Independent_of_Glucose_Control\" >Chronic Kidney Disease: Renal Protection Independent of Glucose Control<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-6\" href=\"https:\/\/www.delveinsight.com\/blog\/expansion-of-glp-1-drugs\/#Obstructive_Sleep_Apnea_The_Newest_Approved_Frontier\" >Obstructive Sleep Apnea: The Newest Approved Frontier<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-7\" href=\"https:\/\/www.delveinsight.com\/blog\/expansion-of-glp-1-drugs\/#The_Neurological_and_Behavioral_Frontier_Alzheimers_Parkinsons_and_Addiction\" >The Neurological and Behavioral Frontier: Alzheimer&#8217;s, Parkinson&#8217;s, and Addiction<\/a><\/li><\/ul><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-8\" href=\"https:\/\/www.delveinsight.com\/blog\/expansion-of-glp-1-drugs\/#The_Pipeline_Whats_Coming_After_Semaglutide_and_Tirzepatide\" >The Pipeline: What&#8217;s Coming After Semaglutide and Tirzepatide<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-9\" href=\"https:\/\/www.delveinsight.com\/blog\/expansion-of-glp-1-drugs\/#The_Market_Opportunity_Why_%E2%80%9CMulti-Disease%E2%80%9D_Is_a_Commercial_Strategy_Not_Just_a_Clinical_One\" >The Market Opportunity: Why &#8220;Multi-Disease&#8221; Is a Commercial Strategy, Not Just a Clinical One<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-10\" href=\"https:\/\/www.delveinsight.com\/blog\/expansion-of-glp-1-drugs\/#Whats_Next_The_Direction_of_Travel\" >What&#8217;s Next: The Direction of Travel<\/a><\/li><\/ul><\/nav><\/div>\n\n<p><strong><em>Summary<\/em><\/strong><\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><em>GLP-1 therapies are evolving beyond diabetes and obesity management into a multi-indication cardiometabolic drug platform, with expanding applications across cardiovascular disease, chronic kidney disease (CKD), metabolic dysfunction-associated steatohepatitis (MASH), and obstructive sleep apnea (OSA).<\/em><\/li>\n\n\n\n<li><em>Oral GLP-1 therapies, including Novo\u2019s semaglutide, Eli Lilly\u2019s orforglipron, and Structure Therapeutics&#8217; aleniglipron, could drive market growth by improving convenience, adherence, and accessibility beyond injectable treatments.<\/em><\/li>\n\n\n\n<li><em>The development pipeline is becoming increasingly competitive and diversified, with Eli Lilly\u2019s retatrutide, a triple GLP-1\/GIP\/glucagon receptor agonist, advancing alongside orforglipron and other candidates. Novo Nordisk\u2019s CagriSema, cagrilintide, and amycretin, together with Amgen\u2019s MariTide and Viking Therapeutics\u2019 VK2735, further intensify competition across oral therapies, combination treatments, and longer-acting formulations.<\/em><\/li>\n<\/ul>\n\n\n\n<p>Five years ago, GLP-1 receptor agonists were a diabetes story with a weight-loss subplot. Today, that subplot has become several new headlines of its own. Cardiologists are prescribing them to cut heart attack risk. Hepatologists are using them to reverse liver scarring. Nephrologists are watching them slow kidney decline. Sleep specialists are studying their effect on apnea severity. And neurologists are now asking, cautiously, whether they might do something for the brain.<\/p>\n\n\n\n<p>What began as a <a href=\"https:\/\/www.delveinsight.com\/report-store\/type-2-diabetes-market\">treatment for type 2 diabetes mellitus (T2DM)<\/a> has evolved into one of the broadest, fastest-expanding drug platforms in modern pharmacology. The industry increasingly describes GLP-1 receptor agonists not as an obesity drug class, but as a multi-indication cardiometabolic platform, and the label expansions, GLP-1 obesity drugs pipeline data, and GLP-1 market size forecasts all back that framing up.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-from-glycemic-control-to-global-phenomenon-a-quick-recap\"><span class=\"ez-toc-section\" id=\"From_Glycemic_Control_to_Global_Phenomenon_A_Quick_Recap\"><\/span><strong>From Glycemic Control to Global Phenomenon: A Quick Recap<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>The first injectable GLP-1 receptor agonist was approved for T2DM roughly a quarter-century ago. Weight management followed just over a decade later, and that approval is what turned <strong>semaglutide <\/strong>(OZEMPIC\/WEGOVY) and <strong>tirzepatide <\/strong>(MOUNJARO\/ZEPBOUND) into household names and anchored today&#8217;s GLP-1 receptor agonist market. Since then, the pace of label expansion has accelerated sharply: secondary cardiovascular risk reduction, obstructive sleep apnea, and metabolic dysfunction-associated steatohepatitis (MASH) have all been added to GLP-1 labels in rapid succession.<\/p>\n\n\n\n<p>The other major inflection point has been the arrival of oral GLP-1 medications. For years, the entire class was injectable-only, which limited uptake among needle-averse patients. That changed with oral GLP-1 drugs for weight loss such as oral semaglutide (RYBELSUS, and now the higher-dose WEGOVY 25 mg pill), and more decisively with orforglipron (FOUNDAYO), Eli Lilly&#8217;s new oral GLP-1, the first oral small-molecule GLP-1 of its kind, which removed the food-and-water timing restrictions that made earlier oral GLP-1 drugs cumbersome. The entry of <a href=\"https:\/\/www.delveinsight.com\/blog\/oral-glp1-in-obesity-treatment\">oral GLP-1 for weight loss<\/a> matters commercially as much as clinically: it collapses the biggest adoption barrier in the category and is a major reason analysts expect oral GLP-1 medications to be the fastest-growing segment of the GLP-1 market through the next decade. Structure Therapeutics&#8217; aleniglipron and Novo Nordisk&#8217;s own oral candidates mean GLP-1 oral competition is now one of the most closely watched fronts in the entire GLP-1 drug market.<\/p>\n\n\n\n<p>The strategic logic is straightforward. Obesity, insulin resistance, and chronic low-grade inflammation sit upstream of an enormous share of chronic disease, cardiovascular, renal, hepatic, respiratory, orthopedic, and possibly neurological. A therapy that intervenes at that metabolic root has a plausible mechanistic case for benefit across all of those downstream conditions. That is exactly the case GLP-1 manufacturers are now making, trial by trial, and it is reshaping how the GLP-1 receptor agonist market itself is segmented and forecast.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-expanding-beyond-weight-loss-the-growing-therapeutic-potential-of-glp-1s\"><span class=\"ez-toc-section\" id=\"Expanding_Beyond_Weight_Loss_The_Growing_Therapeutic_Potential_of_GLP-1s\"><\/span><strong>Expanding Beyond Weight Loss: The Growing Therapeutic Potential of GLP-1s<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>GLP-1-based therapies are rapidly evolving beyond diabetes and <a href=\"https:\/\/www.delveinsight.com\/blog\/weight-loss-obesity-market\">obesity management<\/a>, with emerging evidence supporting their potential across multiple chronic diseases. Cardiovascular disease, MASH, chronic kidney disease, and obstructive sleep apnea are expanding the clinical and commercial scope of this drug class, while neurological disorders and substance use disorders represent promising areas of investigation. By targeting underlying metabolic dysfunction, these therapies may address interconnected disease pathways and improve long-term patient outcomes. This broader therapeutic potential is also reshaping payer perceptions, reimbursement priorities, and the commercial outlook for GLP-1-based treatments.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-cardiovascular-disease-the-indication-that-changed-the-payer-conversation\"><span class=\"ez-toc-section\" id=\"Cardiovascular_Disease_The_Indication_That_Changed_the_Payer_Conversation\"><\/span><strong>Cardiovascular Disease: The Indication That Changed the Payer Conversation<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n\n\n\n<p>The single most consequential expansion has been cardiovascular. Trials establishing that semaglutide reduces cardiovascular risk in overweight adults, independent of diabetes status, fundamentally shifted how payers and physicians think about these drugs. GLP-1 therapy is no longer a &#8220;lifestyle&#8221; or cosmetic intervention in the eyes of insurers; it is a cardioprotective one, and that reframing has real implications for reimbursement policy. Tirzepatide is following the same path. Data from Eli Lilly&#8217;s cardiovascular outcomes program show a meaningful reduction in major adverse cardiovascular events (MACE), heart attack, stroke, and cardiovascular death, in patients with T2DM, with an FDA decision on this new indication expected in 2026.<\/p>\n\n\n\n<p>Heart failure with preserved ejection fraction (HFpEF), a notoriously difficult-to-treat condition with few effective therapies, is another frontier. Emerging data suggest GLP-1 and dual-agonist therapies can meaningfully outperform older standards of care on relative risk reduction in HFpEF populations, while also improving symptoms and functional capacity.<\/p>\n\n\n\n<p>The patient burden behind this expansion is enormous. Cardiovascular disease remains the leading cause of death worldwide, responsible for roughly 18 million deaths a year, and a large share of that burden sits squarely in patients who are also living with obesity, insulin resistance, or T2DM, the exact population GLP-1 therapy was originally designed for. In the US alone, an estimated <strong>6.7 million<\/strong> adults are currently <a href=\"https:\/\/www.delveinsight.com\/report-store\/heart-failure-market\">living with heart failure<\/a>, a figure projected to climb past <strong>8.7 million<\/strong> by 2030 and beyond <strong>11 million<\/strong> by 2050, with lifetime risk now estimated at nearly <strong>1 in 4 people<\/strong>.&nbsp;<\/p>\n\n\n\n<p>HFpEF in particular has historically been a frustrating diagnosis for patients and clinicians alike: it disproportionately affects older adults and those with obesity, carries a high hospital readmission rate, and until recently offered few therapies that meaningfully improved how patients actually felt day to day, as opposed to just stabilizing lab values. A drug class that can simultaneously address the metabolic driver and the downstream cardiac strain represents a rare chance to reduce hospitalizations, caregiver burden, and long-term disability in a population that has had very few good options.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-mash-and-the-liver-reversing-damage-not-just-managing-risk\"><span class=\"ez-toc-section\" id=\"MASH_and_the_Liver_Reversing_Damage_Not_Just_Managing_Risk\"><\/span><strong>MASH and the Liver: Reversing Damage, Not Just Managing Risk<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n\n\n\n<p>Metabolic dysfunction-associated steatohepatitis (MASH), formerly known as NASH, has emerged as one of the most closely watched new GLP-1 indications. Unlike many chronic disease targets, MASH trials are showing something rarer: evidence of fibrosis improvement, not just risk-factor management. Semaglutide at higher doses has demonstrated the potential to resolve liver fibrosis in trial populations, a result that matters enormously in a therapeutic area with almost no approved pharmacological options until recently. For a disease projected to become one of the leading causes of liver transplantation, a GLP-1-based approach that treats the metabolic driver rather than just the hepatic endpoint is a genuinely differentiated value proposition, and one competitors in the MASH space are now racing to match.<\/p>\n\n\n\n<p>The burden MASH places on patients is easy to underestimate because the disease is often silent until it is advanced. Globally, an estimated <strong>1.3 billion<\/strong> people, roughly one in six adults, now live with the broader spectrum of fatty liver disease (MASLD), a figure that has grown by more than <strong>140%<\/strong> since 1990 and is projected to reach <strong>1.8 billion<\/strong> by 2050. As per DelveInsight analysis, MASH affects an estimated <strong>1.5\u20136.5%<\/strong> of US adults, representing approximately 9\u201315 million individuals, with <a href=\"https:\/\/www.delveinsight.com\/blog\/metabolic-associated-steatohepatitis-treatment-landscape\">MASH prevalence<\/a> projected to increase by <strong>63%<\/strong> by 2030.<\/p>\n\n\n\n<p>A meaningful subset of that population progresses to MASH, the more aggressive, inflammatory form of the disease that drives fibrosis.&nbsp;<\/p>\n\n\n\n<p>Many of these patients live for years with progressive liver scarring without symptoms, only to present with cirrhosis, liver failure, or a diagnosis of hepatocellular carcinoma once the damage is largely irreversible. Because MASH tracks so closely with obesity and T2DM, patients are often managing multiple chronic conditions simultaneously, multiplying appointments, monitoring, and the cumulative toll of disease on daily life. A therapy that can halt or reverse fibrosis earlier in that trajectory doesn&#8217;t just change a lab value; it changes whether a patient eventually needs a liver transplant at all.<\/p>\n\n\n\n<figure class=\"wp-block-image size-large\"><img loading=\"lazy\" decoding=\"async\" width=\"1024\" height=\"404\" src=\"https:\/\/www.delveinsight.com\/blog\/wp-content\/uploads\/2026\/10\/GLP-1-Indications-Beyond-Obesity-and-Diabetes-1024x404.webp\" alt=\"GLP-1-Indications-Beyond-Obesity-and-Diabetes\" class=\"wp-image-36344\" srcset=\"https:\/\/www.delveinsight.com\/blog\/wp-content\/uploads\/2026\/10\/GLP-1-Indications-Beyond-Obesity-and-Diabetes-1024x404.webp 1024w, https:\/\/www.delveinsight.com\/blog\/wp-content\/uploads\/2026\/10\/GLP-1-Indications-Beyond-Obesity-and-Diabetes-300x118.webp 300w, https:\/\/www.delveinsight.com\/blog\/wp-content\/uploads\/2026\/10\/GLP-1-Indications-Beyond-Obesity-and-Diabetes-150x59.webp 150w, https:\/\/www.delveinsight.com\/blog\/wp-content\/uploads\/2026\/10\/GLP-1-Indications-Beyond-Obesity-and-Diabetes-768x303.webp 768w, https:\/\/www.delveinsight.com\/blog\/wp-content\/uploads\/2026\/10\/GLP-1-Indications-Beyond-Obesity-and-Diabetes-1536x606.webp 1536w, https:\/\/www.delveinsight.com\/blog\/wp-content\/uploads\/2026\/10\/GLP-1-Indications-Beyond-Obesity-and-Diabetes.webp 1920w\" sizes=\"auto, (max-width: 1024px) 100vw, 1024px\" \/><\/figure>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-chronic-kidney-disease-renal-protection-independent-of-glucose-control\"><span class=\"ez-toc-section\" id=\"Chronic_Kidney_Disease_Renal_Protection_Independent_of_Glucose_Control\"><\/span><strong>Chronic Kidney Disease: Renal Protection Independent of Glucose Control<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n\n\n\n<p>Chronic kidney disease (CKD) is shaping up to be another major growth vector. Clinical evidence increasingly points to renal-protective effects that occur independently of a patient&#8217;s glycemic status, suggesting the mechanism runs deeper than glucose control alone, likely involving reduced inflammation, better hemodynamics, and less metabolic strain on the kidneys.<\/p>\n\n\n\n<p>Given how frequently CKD, T2DM, obesity, and cardiovascular disease cluster in the same patients, a single therapy addressing all four simultaneously is a compelling proposition for value-based and bundled-payment care models, where reducing total disease burden per patient, not treating one diagnosis at a time, is the goal.<\/p>\n\n\n\n<p>CKD is one of the most under-recognized chronic conditions in terms of patient burden, largely because early-stage kidney decline produces few noticeable symptoms. Global estimates now put CKD prevalence at nearly <strong>800 million<\/strong> people, more than double the figure recorded in 1990, making it one of the fastest-growing non-communicable disease burdens worldwide, with kidney disease linked to a death roughly every 20 seconds. As per DelveInsight analysis, in 2025, there were approximately <strong>82.5 million <\/strong>prevalent and nearly <strong>14.5 million<\/strong> <a href=\"https:\/\/www.delveinsight.com\/report-store\/chronic-kidney-disease-chronic-renal-failure-market\">diagnosed prevalent cases of CKD<\/a> in the 7MM.<\/p>\n\n\n\n<p>By the time patients experience fatigue, swelling, or other overt signs, meaningful kidney function has often already been lost. For patients who progress to end-stage kidney disease, the burden escalates dramatically: dialysis several times a week, transplant waitlists that can run years, and a sharply reduced quality of life. Slowing that progression earlier, especially in the diabetic and obese populations where CKD most often takes hold, could meaningfully delay or prevent some of the most burdensome and costly outcomes in all of chronic disease care.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-obstructive-sleep-apnea-the-newest-approved-frontier\"><span class=\"ez-toc-section\" id=\"Obstructive_Sleep_Apnea_The_Newest_Approved_Frontier\"><\/span><strong>Obstructive Sleep Apnea: The Newest Approved Frontier<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n\n\n\n<p>Obstructive sleep apnea (OSA) has become one of the more recently approved indications, with tirzepatide showing significant reductions in apnea-hypopnea index alongside its weight-loss effect. This is a particularly clean example of the &#8220;treat the root cause&#8221; thesis: a large share of OSA cases are driven by excess adipose tissue around the airway, so a drug that reduces that tissue produces a downstream respiratory benefit almost as a matter of physiology.<\/p>\n\n\n\n<p>OSA&#8217;s burden is often dismissed as a quality-of-life nuisance rather than a serious medical condition, but that undersells it considerably. Global estimates suggest close to <strong>1 billion<\/strong> adults worldwide have some degree of obstructive sleep apnea, with roughly <strong>425 million<\/strong> living with moderate-to-severe disease severe enough to warrant treatment, and a large share of cases remain undiagnosed. Untreated OSA is linked to elevated cardiovascular risk, daytime fatigue that affects safety at work and on the road, and a steady erosion of sleep quality that compounds over years. Many patients struggle with adherence to the standard CPAP therapy, finding it cumbersome or uncomfortable for nightly use. A pharmacological option that addresses the excess tissue driving airway obstruction gives patients and clinicians a genuinely new lever to pull, particularly for those who have already failed or abandoned device-based therapy.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-the-neurological-and-behavioral-frontier-alzheimer-s-parkinson-s-and-addiction\"><span class=\"ez-toc-section\" id=\"The_Neurological_and_Behavioral_Frontier_Alzheimers_Parkinsons_and_Addiction\"><\/span><strong>The Neurological and Behavioral Frontier: Alzheimer&#8217;s, Parkinson&#8217;s, and Addiction<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n\n\n\n<p>This is the most speculative and most closely watched area of GLP-1 expansion. Observational research has associated long-term GLP-1 use with meaningfully reduced dementia risk in some patient populations, and active trials are now testing GLP-1 therapy directly in Alzheimer&#8217;s disease and Parkinson&#8217;s disease. The proposed mechanisms include reduced neuroinflammation, improved cerebral glucose metabolism, and vascular protection, though it&#8217;s worth noting this evidence is still early, and causality has not been established the way it has for cardiovascular or renal outcomes.<\/p>\n\n\n\n<p>Equally striking is the growing interest in GLP-1 therapy for substance use disorder. Preclinical and early clinical signals suggest these drugs may dampen reward-pathway activity tied to alcohol, nicotine, and other substances, plausible given that GLP-1 receptors are expressed in brain regions tied to craving and reward. Pharmacy and clinical conference sessions in 2026 have specifically flagged chronic kidney disease and substance use disorder as the next frontier for the class, alongside orthopedic and osteoarthritis applications, where semaglutide and tirzepatide have both shown meaningful pain reduction, though it remains debated how much of that benefit is simply weight-related joint offloading versus a separate anti-inflammatory effect.<\/p>\n\n\n\n<p>The burden here is almost impossible to overstate. Worldwide, more than <strong>55 million<\/strong> people are estimated to be living with dementia, of which Alzheimer&#8217;s accounts for an estimated <strong>60\u201380%<\/strong> of cases; in the US alone, roughly <strong>7.4 million<\/strong> adults aged 65 and older currently live with <a href=\"https:\/\/www.delveinsight.com\/report-store\/alzheimers-disease-ad-market\">clinical Alzheimer&#8217;s dementia<\/a>, a number projected to nearly double to <strong>13.8 million<\/strong> by 2060 absent a disease-modifying breakthrough. Parkinson&#8217;s disease affects an estimated <strong>11.7 million<\/strong> people globally, a figure that has more than doubled since 1990 and is projected to exceed <strong>14 million<\/strong> by 2040, with its own long, degenerative course of motor and non-motor symptoms that worsen over years and few therapies that slow the underlying disease process rather than just masking symptoms.&nbsp;<\/p>\n\n\n\n<p>Dementia and Alzheimer&#8217;s also place an enormous and often underappreciated strain on family caregivers who absorb much of the day-to-day burden. Substance use disorder, meanwhile, remains chronically undertreated relative to its prevalence, in part because existing pharmacological options are limited and relapse rates remain high. Even a modest, well-validated effect in any one of these areas would represent a meaningful addition to a treatment landscape that has seen relatively little pharmacological innovation in decades.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-the-pipeline-what-s-coming-after-semaglutide-and-tirzepatide\"><span class=\"ez-toc-section\" id=\"The_Pipeline_Whats_Coming_After_Semaglutide_and_Tirzepatide\"><\/span><strong>The Pipeline: What&#8217;s Coming After Semaglutide and Tirzepatide<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>The <a href=\"https:\/\/www.delveinsight.com\/blog\/obesity-drugs-launch\">next generation of the GLP-1 drug<\/a> market is being built around three strategic axes, more efficacy, less burden, and broader mechanism, and the competitive race to own that next wave has only intensified through 2026. Eli Lilly&#8217;s pipeline beyond tirzepatide is now its most closely watched growth story: retatrutide, a triple agonist hitting the GLP-1, GIP, and glucagon receptors, remains the efficacy leader in the class, having reported more than 28% weight loss in Phase 3 obesity trials, with three additional Phase 3 obesity readouts and active MASH trials expected before the end of 2026. Alongside it, <strong>orforglipron<\/strong>, Lilly&#8217;s new oral GLP-1 and the first oral small-molecule GLP-1 drug of its kind, is moving toward regulatory filings for obesity, with the <strong>ATTAIN-MAINTAIN study<\/strong> assessing how well patients maintain weight loss after switching from injectable semaglutide or tirzepatide to the pill. Lilly&#8217;s mid-stage bench is also deepening, with bimagrumab, eloralintide, and mazdutide all advancing as it builds out a GLP-1 obesity drugs pipeline that extends well past its current blockbusters.<\/p>\n\n\n\n<figure class=\"wp-block-image size-large\"><img loading=\"lazy\" decoding=\"async\" width=\"1024\" height=\"377\" src=\"https:\/\/www.delveinsight.com\/blog\/wp-content\/uploads\/2026\/10\/Comparison-of-Emerging-GLP-1-Drugs-Under-Development-1024x377.webp\" alt=\"Comparison-of-Emerging-GLP-1-Drugs-Under-Development\" class=\"wp-image-36343\" srcset=\"https:\/\/www.delveinsight.com\/blog\/wp-content\/uploads\/2026\/10\/Comparison-of-Emerging-GLP-1-Drugs-Under-Development-1024x377.webp 1024w, https:\/\/www.delveinsight.com\/blog\/wp-content\/uploads\/2026\/10\/Comparison-of-Emerging-GLP-1-Drugs-Under-Development-300x110.webp 300w, https:\/\/www.delveinsight.com\/blog\/wp-content\/uploads\/2026\/10\/Comparison-of-Emerging-GLP-1-Drugs-Under-Development-150x55.webp 150w, https:\/\/www.delveinsight.com\/blog\/wp-content\/uploads\/2026\/10\/Comparison-of-Emerging-GLP-1-Drugs-Under-Development-768x282.webp 768w, https:\/\/www.delveinsight.com\/blog\/wp-content\/uploads\/2026\/10\/Comparison-of-Emerging-GLP-1-Drugs-Under-Development-1536x565.webp 1536w, https:\/\/www.delveinsight.com\/blog\/wp-content\/uploads\/2026\/10\/Comparison-of-Emerging-GLP-1-Drugs-Under-Development.webp 1920w\" sizes=\"auto, (max-width: 1024px) 100vw, 1024px\" \/><\/figure>\n\n\n\n<p>Lilly is no longer running unopposed, though. The latest round of emerging-therapy news has centered on <strong>Structure Therapeutics&#8217; oral candidate aleniglipron<\/strong>, which posted Phase 2b data showing 11.3% placebo-adjusted weight loss at its 120 mg dose and 15.3% at 240 mg, strong enough that the company is planning late-stage studies around mid-2026, and strong enough that Lilly&#8217;s own share price dipped on investor concern about a more crowded oral GLP-1 field. Novo Nordisk, for its part, continues to press its own next-generation lineup: an oral version of WEGOVY, the amylin-GLP-1 combination <strong>CagriSema<\/strong>, a standalone cagrilintide program, and amycretin are all advancing, while <strong>Amgen&#8217;s MariTide<\/strong>, a monthly antibody-peptide conjugate notable for weight loss that persisted even after dosing stopped in Phase 2, and <strong>Viking Therapeutics&#8217; VK2735<\/strong>, now in two late-stage subcutaneous studies with oral development alongside it, round out a pipeline that has genuinely diversified beyond a single dominant mechanism.<\/p>\n\n\n\n<p>More than <strong>20 candidates<\/strong> are now in Phase 2 or Phase 3 development, spanning dual agonists, triple agonists, oral small molecules, and monthly injectable formats. That diversity is the clearest signal yet that next-generation GLP-1 drugs are no longer just a race to out-dose semaglutide; they&#8217;re a genuine platform competition, with format (oral versus injectable), durability, and breadth of indication all now just as commercially important as raw weight-loss percentage.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-the-market-opportunity-why-multi-disease-is-a-commercial-strategy-not-just-a-clinical-one\"><span class=\"ez-toc-section\" id=\"The_Market_Opportunity_Why_%E2%80%9CMulti-Disease%E2%80%9D_Is_a_Commercial_Strategy_Not_Just_a_Clinical_One\"><\/span><strong>The Market Opportunity: Why &#8220;Multi-Disease&#8221; Is a Commercial Strategy, Not Just a Clinical One<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>The <a href=\"https:\/\/www.delveinsight.com\/report-store\/glp-1-therapies-market\">global GLP-1 therapies market<\/a> is valued at approximately <strong>USD 62.83 billion<\/strong> in 2025 and is forecast to reach <strong>USD 254.19 billion<\/strong> by 2034. Market growth is primarily driven by the increasing use of GLP-1 therapies for obesity and long-term weight management, the strong commercial performance of tirzepatide- and semaglutide-based treatments, and the introduction of oral GLP-1 formulations. The global GLP-1 therapies market is expected to expand at a <strong>CAGR of 16.8%<\/strong> during the forecast period from 2026 to 2034.<\/p>\n\n\n\n<p>The strategic rationale behind this growth is as much commercial as clinical. Indication diversification insulates GLP-1 manufacturers from reimbursement pressure or pricing scrutiny in any single therapeutic category, while simultaneously expanding the addressable patient population well beyond people who qualify for an obesity or diabetes diagnosis alone. With more than a billion people globally living with obesity, and only a small fraction currently on pharmacotherapy, the total addressable market for a genuinely multi-indication platform dwarfs what diabetes treatment alone could ever support.<\/p>\n\n\n\n<p>Type 2 diabetes still represents the largest single application segment of the GLP-1 drug market today, but its relative share is expected to shrink as MASH, sleep apnea, cardiovascular, and Alzheimer&#8217;s-related indications carve out growing slices of the pie. Oral GLP-1 drugs and long-acting formulations are expected to be the fastest-growing product segments of the GLP-1 market size through the next decade, driven by adherence and access advantages over weekly injections, a dynamic that is already reshaping how GLP-1 manufacturers prioritize their own pipelines.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-what-s-next-the-direction-of-travel\"><span class=\"ez-toc-section\" id=\"Whats_Next_The_Direction_of_Travel\"><\/span><strong>What&#8217;s Next: The Direction of Travel<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>Two things seem clear heading into the second half of the decade. First, the <a href=\"https:\/\/www.delveinsight.com\/report-store\/glucagon-like-peptide1-glp1-agonists-market-forecast\">GLP-1 receptor agonist market<\/a> is no longer competing primarily on weight-loss percentage points; it&#8217;s competing on breadth of evidence, durability of effect, and oral versus injectable format convenience. Second, the indications furthest from the original diabetes and obesity core, Alzheimer&#8217;s, Parkinson&#8217;s, substance use disorder, are exactly where the next wave of differentiation and headline-grabbing data is likely to come from, even though they carry the highest scientific uncertainty today.<\/p>\n\n\n\n<p>For an industry accustomed to single-indication blockbusters, GLP-1 receptor agonists represent something structurally different: a platform technology being validated one organ system at a time. The weight-loss story got the world&#8217;s attention. The multi-disease story, and the GLP-1 obesity drugs latest developments that keep extending it, is what will determine how large and how permanent this therapeutic category ultimately becomes.<\/p>\n\n\n\n<figure class=\"wp-block-image size-large\"><a href=\"https:\/\/www.delveinsight.com\/report-store\/glucagon-like-peptide1-glp1-agonists-market-forecast\"><img loading=\"lazy\" decoding=\"async\" width=\"1024\" height=\"194\" src=\"https:\/\/www.delveinsight.com\/blog\/wp-content\/uploads\/2026\/06\/GLP-1-Agonists-Market-Outlook-1024x194.webp\" alt=\"GLP-1 Agonists Market Outlook\" class=\"wp-image-35423\" srcset=\"https:\/\/www.delveinsight.com\/blog\/wp-content\/uploads\/2026\/06\/GLP-1-Agonists-Market-Outlook-1024x194.webp 1024w, https:\/\/www.delveinsight.com\/blog\/wp-content\/uploads\/2026\/06\/GLP-1-Agonists-Market-Outlook-300x57.webp 300w, https:\/\/www.delveinsight.com\/blog\/wp-content\/uploads\/2026\/06\/GLP-1-Agonists-Market-Outlook-150x28.webp 150w, https:\/\/www.delveinsight.com\/blog\/wp-content\/uploads\/2026\/06\/GLP-1-Agonists-Market-Outlook-768x145.webp 768w, https:\/\/www.delveinsight.com\/blog\/wp-content\/uploads\/2026\/06\/GLP-1-Agonists-Market-Outlook-1536x291.webp 1536w, https:\/\/www.delveinsight.com\/blog\/wp-content\/uploads\/2026\/06\/GLP-1-Agonists-Market-Outlook.webp 1584w\" sizes=\"auto, (max-width: 1024px) 100vw, 1024px\" \/><\/a><\/figure>\n","protected":false},"excerpt":{"rendered":"<p>Summary Five years ago, GLP-1 receptor agonists were a diabetes story with a weight-loss subplot. Today, that subplot has become several new headlines of its own. Cardiologists are prescribing them to cut heart attack risk. Hepatologists are using them to reverse liver scarring. Nephrologists are watching them slow kidney decline. Sleep specialists are studying their [&hellip;]<\/p>\n","protected":false},"author":14,"featured_media":36341,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"_editorskit_title_hidden":false,"_editorskit_reading_time":0,"_editorskit_is_block_options_detached":false,"_editorskit_block_options_position":"{}","advgb_blocks_editor_width":"","advgb_blocks_columns_visual_guide":"","footnotes":""},"categories":[17],"tags":[3702,23169,22409,22318,1173,2858,23018,22291,17668,21050,22172],"industry":[17225],"therapeutic_areas":[17240],"class_list":["post-36338","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-articles","tag-chronic-kidney-disease","tag-glp-1-drugs","tag-glp-1-receptor","tag-mash","tag-obesity","tag-obstructive-sleep-apnea","tag-oral-glp-1","tag-ozempic","tag-semaglutide","tag-wegovy","tag-zepbound","industry-pharmaceutical","therapeutic_areas-endocrinology-and-metabolic-disorders"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v27.9 (Yoast SEO v27.9) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>The Expansion of GLP-1 Drugs: From Obesity to Multi-Indication<\/title>\n<meta name=\"description\" content=\"GLP-1 drugs are evolving beyond diabetes and obesity management into a multi-indication cardiometabolic drug platform.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.delveinsight.com\/blog\/expansion-of-glp-1-drugs\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"The Expansion of GLP-1 Drugs: From Obesity to Multi-Indication\" \/>\n<meta property=\"og:description\" content=\"GLP-1 drugs are evolving beyond diabetes and obesity management into a multi-indication cardiometabolic drug platform.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.delveinsight.com\/blog\/expansion-of-glp-1-drugs\" \/>\n<meta property=\"og:site_name\" content=\"DelveInsight Business Research\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/\" \/>\n<meta property=\"article:published_time\" content=\"2026-10-26T11:45:00+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.delveinsight.com\/blog\/wp-content\/uploads\/2026\/10\/expansion-of-glp-1-drugs.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"466\" \/>\n\t<meta property=\"og:image:height\" content=\"284\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/webp\" \/>\n<meta name=\"author\" content=\"Sandeep Joshi\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:site\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Sandeep Joshi\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"15 minutes\" \/>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"The Expansion of GLP-1 Drugs: From Obesity to Multi-Indication","description":"GLP-1 drugs are evolving beyond diabetes and obesity management into a multi-indication cardiometabolic drug platform.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.delveinsight.com\/blog\/expansion-of-glp-1-drugs","og_locale":"en_US","og_type":"article","og_title":"The Expansion of GLP-1 Drugs: From Obesity to Multi-Indication","og_description":"GLP-1 drugs are evolving beyond diabetes and obesity management into a multi-indication cardiometabolic drug platform.","og_url":"https:\/\/www.delveinsight.com\/blog\/expansion-of-glp-1-drugs","og_site_name":"DelveInsight Business Research","article_publisher":"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/","article_published_time":"2026-10-26T11:45:00+00:00","og_image":[{"width":466,"height":284,"url":"https:\/\/www.delveinsight.com\/blog\/wp-content\/uploads\/2026\/10\/expansion-of-glp-1-drugs.webp","type":"image\/webp"}],"author":"Sandeep Joshi","twitter_card":"summary_large_image","twitter_creator":"@DelveInsight","twitter_site":"@DelveInsight","twitter_misc":{"Written by":"Sandeep Joshi","Est. reading time":"15 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.delveinsight.com\/blog\/expansion-of-glp-1-drugs#article","isPartOf":{"@id":"https:\/\/www.delveinsight.com\/blog\/expansion-of-glp-1-drugs"},"author":{"name":"Sandeep Joshi","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/f1eefd8dd4afdb0617d6166f8b301e0a"},"headline":"GLP-1 Drugs Are Moving Beyond Weight Loss\u2014But How Big Can the Opportunity Become?","datePublished":"2026-10-26T11:45:00+00:00","mainEntityOfPage":{"@id":"https:\/\/www.delveinsight.com\/blog\/expansion-of-glp-1-drugs"},"wordCount":3025,"image":{"@id":"https:\/\/www.delveinsight.com\/blog\/expansion-of-glp-1-drugs#primaryimage"},"thumbnailUrl":"https:\/\/www.delveinsight.com\/blog\/wp-content\/uploads\/2026\/10\/expansion-of-glp-1-drugs.webp","keywords":["Chronic Kidney Disease","GLP-1 Drugs","GLP-1 receptor","MASH","obesity","obstructive sleep apnea","Oral GLP-1","OZEMPIC","Semaglutide","Wegovy","ZEPBOUND"],"articleSection":["Articles"],"inLanguage":"en-US","copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/www.delveinsight.com\/blog\/#organization"}},{"@type":"WebPage","@id":"https:\/\/www.delveinsight.com\/blog\/expansion-of-glp-1-drugs","url":"https:\/\/www.delveinsight.com\/blog\/expansion-of-glp-1-drugs","name":"The Expansion of GLP-1 Drugs: From Obesity to Multi-Indication","isPartOf":{"@id":"https:\/\/www.delveinsight.com\/blog\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.delveinsight.com\/blog\/expansion-of-glp-1-drugs#primaryimage"},"image":{"@id":"https:\/\/www.delveinsight.com\/blog\/expansion-of-glp-1-drugs#primaryimage"},"thumbnailUrl":"https:\/\/www.delveinsight.com\/blog\/wp-content\/uploads\/2026\/10\/expansion-of-glp-1-drugs.webp","datePublished":"2026-10-26T11:45:00+00:00","author":{"@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/f1eefd8dd4afdb0617d6166f8b301e0a"},"description":"GLP-1 drugs are evolving beyond diabetes and obesity management into a multi-indication cardiometabolic drug platform.","inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.delveinsight.com\/blog\/expansion-of-glp-1-drugs"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.delveinsight.com\/blog\/expansion-of-glp-1-drugs#primaryimage","url":"https:\/\/www.delveinsight.com\/blog\/wp-content\/uploads\/2026\/10\/expansion-of-glp-1-drugs.webp","contentUrl":"https:\/\/www.delveinsight.com\/blog\/wp-content\/uploads\/2026\/10\/expansion-of-glp-1-drugs.webp","width":466,"height":284,"caption":"expansion-of-glp-1-drugs"},{"@type":"WebSite","@id":"https:\/\/www.delveinsight.com\/blog\/#website","url":"https:\/\/www.delveinsight.com\/blog\/","name":"DelveInsight Business Research","description":"Blog","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.delveinsight.com\/blog\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/f1eefd8dd4afdb0617d6166f8b301e0a","name":"Sandeep Joshi","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/7676451175fe155887a18ffb50e674b270d87436a3fc34ca206f86921cddf4cd?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/7676451175fe155887a18ffb50e674b270d87436a3fc34ca206f86921cddf4cd?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/7676451175fe155887a18ffb50e674b270d87436a3fc34ca206f86921cddf4cd?s=96&d=mm&r=g","caption":"Sandeep Joshi"},"sameAs":["http:\/\/Delveinsight.com"]}]}},"author_meta":{"display_name":"Sandeep Joshi","author_link":"https:\/\/www.delveinsight.com\/blog\/author\/sjoshidelveinsight-com"},"featured_img":"https:\/\/www.delveinsight.com\/blog\/wp-content\/uploads\/2026\/10\/expansion-of-glp-1-drugs-300x183.webp","coauthors":[],"tax_additional":{"categories":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Articles<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">Articles<\/span>"]},"tags":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Chronic Kidney Disease<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">GLP-1 Drugs<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">GLP-1 receptor<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">MASH<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">obesity<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">obstructive sleep apnea<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Oral GLP-1<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">OZEMPIC<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Semaglutide<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Wegovy<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">ZEPBOUND<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">Chronic Kidney Disease<\/span>","<span class=\"advgb-post-tax-term\">GLP-1 Drugs<\/span>","<span class=\"advgb-post-tax-term\">GLP-1 receptor<\/span>","<span class=\"advgb-post-tax-term\">MASH<\/span>","<span class=\"advgb-post-tax-term\">obesity<\/span>","<span class=\"advgb-post-tax-term\">obstructive sleep apnea<\/span>","<span class=\"advgb-post-tax-term\">Oral GLP-1<\/span>","<span class=\"advgb-post-tax-term\">OZEMPIC<\/span>","<span class=\"advgb-post-tax-term\">Semaglutide<\/span>","<span class=\"advgb-post-tax-term\">Wegovy<\/span>","<span class=\"advgb-post-tax-term\">ZEPBOUND<\/span>"]}},"comment_count":"0","relative_dates":{"created":"Posted 5 hours ago","modified":"Updated 48 minutes ago"},"absolute_dates":{"created":"Posted on Oct 26, 2026","modified":"Updated on Oct 26, 2026"},"absolute_dates_time":{"created":"Posted on Oct 26, 2026 5:15 pm","modified":"Updated on Oct 26, 2026 1:15 pm"},"featured_img_caption":"expansion-of-glp-1-drugs","series_order":"","_links":{"self":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/36338","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/users\/14"}],"replies":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/comments?post=36338"}],"version-history":[{"count":3,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/36338\/revisions"}],"predecessor-version":[{"id":36345,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/36338\/revisions\/36345"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/media\/36341"}],"wp:attachment":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/media?parent=36338"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/categories?post=36338"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/tags?post=36338"},{"taxonomy":"industry","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/industry?post=36338"},{"taxonomy":"therapeutic_areas","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/therapeutic_areas?post=36338"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}